Economic burden of cystic fibrosis care in British Columbia

References

• Sawicki GS, Sellers DE, Robinson WM. High Treatment Burden in Adults with Cystic Fibrosis: Challenges to Disease Self-Management. J Cyst Fibros. 2009;8(2):91–96. doi:10.1016/j.jcf.2008.09.007.
   Google Scholar
• O’Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373(9678):1891–1904. Available from: doi:10.1016/S0140-6736(09)60327-5.
   Google Scholar
• Wilcox P, Chilvers M, Waters I, et al. Cystic Fibrosis - Standards of Care for British Columbia; 2018.
   Google Scholar
• Smyth AR, Bell SC, Bojcin S, et al. European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. J Cyst Fibros. 2014;13:S23–42. 10.1016/j.jcf.2014.03.010.
   Google Scholar
• Farrell PMP, Rosenstein BJB, White TTB, Cystic Fibrosis Foundation, et al. Guidelines for Diagnosis of Cystic Fibrosis in Newborns through Older Adults: Cystic Fibrosis Foundation Consensus Report. J Pediatr. 2008;153(2):S4–S14. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2810958&tool=pmcentrez&rendertype=abstract%5Cnhttp://www.sciencedirect.com/science/article/pii/S0022347608003983
   Google Scholar
• Kerem E, Conway S, Elborn S, Heijerman H, Consensus Committee. Standards of care for patients with cystic fibrosis: a European consensus. J Cyst Fibros. 2005;4(1):7–26. doi:10.1016/j.jcf.2004.12.002.
   Google Scholar
• Parkins MD, Parkins VM, Rendall JC, Elborn S. Changing epidemiology and clinical issues arising in an ageing cystic fibrosis population. Ther Adv Respir Dis. 2011;5(2):105–119. doi:10.1177/1753465810386051.
   Google Scholar
• Christie JD, Edwards LB, Aurora P, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Lung and Heart-Lung Transplantation Report—2009. J Heart Lung Transplant. 2009;28(10):1031–1049. Available from: doi:10.1016/j.healun.2009.08.004.
   Google Scholar
• Kopciuch D, Zaprutko T, Paczkowska A. Costs of treatment of adult patients with cystic fibrosis in Poland and internationally. Public Health. 2017;8:3–9.
   Google Scholar
• Burgel P-R, Durieu I, Chiron R, French Cystic Fibrosis Reference Network Study Group, et al. Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease. Am J Respir Crit Care Med. 2021;204(1):64–73. doi:10.1164/rccm.202011-4153OC.
   Google Scholar
• Ouyang L, Grosse SD, Amendah DD, Schechter MS. Healthcare Expenditures for Privately Insured People With Cystic Fibrosis. Pediatr Pulmonol. 2009;996(September):989–996. doi:10.1002/ppul.21090.
   Google Scholar
• Public Health Agency of Canada. Life and Breath: Respiratory Disease in Canada. Ottawa: Public Health Agency of Canada; 2007.
   Google Scholar
• Quon BS, Rowe MS. State of the Art Review: New and emerging targeted therapies for cystic fibrosis. BMJ. 2016;352:i859 doi: 10.1136/bmj.i859
   Google Scholar
• Ireys HT, Anderson GF, Shaffer TJ, Neff JM. Expenditures for Care of Children With Chronic Illnesses Enrolled in the Washington State Medicaid Program, Fiscal Year 1993. Pediatrics. 1997;100(2 Pt 1):197–204. doi:10.1542/peds.100.2.197.
   Google Scholar
• Baumann U, Stocklossa C, Greiner W, von der Schulenburg J-MG, von der Hardt H. Cost of care and clinical condition in paediatric cystic fibrosis patients. J Cyst Fibros. 2003;2(2):84–90. doi:10.1016/S1569-1993(03)00024-9.
   Google Scholar
• Schrey J, Hollmeyer H, Bluemel M, Staab D, Busse R. Hospitalisation Costs of Cystic Fibrosis. Pharmacoeconomics. 2006;24(10):999–1009. doi:10.2165/00019053-200624100-00007.
   Google Scholar
• Tiemann O, Staab D, Heimeshoff M, Hollmeyer H, Schreyo J. Cost of Illness of Cystic Fibrosis in Germany Results from a Large Cystic Fibrosis Centre. Pharmacoeconomics. 2012;30(9):763–777. doi:10.2165/11588870-000000000-00000.
   Google Scholar
• Angelis A, Kanavos P, López-Bastida J, Linertová R, Nicod E, Serrano-Aguilar P. Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom. BMC Health Services Research. 2015;15(1):1–8.
   Google Scholar
• Ta L, Gt R GF. The cost of medical care for patients with cystic fibrosis in a health maintenance organization. Pediatrics. 1999;103:e72.
   Google Scholar
• Durieu I, Dalon F, Reynaud Q, Lemonnier L, Dehillotte C, Bérard M, Walther D, Viprey M, Van Ganse E, Belhassen M. Temporal trends in healthcare resource use and associated costs of patients with cystic fibrosis. Journal of Cystic Fibrosis. 2022;21(1):88–95.
   Google Scholar
• Jackson AD, Jackson AL, Fletcher G, Doyle G, Harrington M, Zhou S, Cullinane F, Gallagher C, McKone E. Estimating direct cost of cystic fibrosis care using Irish registry healthcare resource utilisation data, 2008–2012. Pharmacoeconomics. 2017;35:1087–101.
   Google Scholar
• Conway S, Balfour-Lynn IM, De Rijcke K, et al. Standards of Care: Framework for the Cystic Fibrosis Centre. J Cyst Fibros. 2014;13:S3–22. 10.1016/j.jcf.2014.03.009.
   Google Scholar
• British Columbia Ministry of Health Medical Services Plan (MSP) Payment Information File. Population Data BC. Data Extract2017. https://www.popdata.bc.ca/data. Accessed October 21, 2022.
   Google Scholar
• Canadian Institute for Health Information. CIHI Data Quality Study of the 2005–2006 Discharge Abstract Database [Internet]. Ottawa; 2009. Available from: https://secure.cihi.ca/free_products/DAD_DQ_study_2005_2006_August_2009_e.pdf.
   Google Scholar
• British Columbia Ministry of Health. PharmaNet. Data Extract. Data Stewardship Committee. 2017. https://www.popdata.bc.ca/data. Accessed October 21, 2022.
   Google Scholar
• British Columbia Ministry of Health. National ambulatory care reporting system. data extract. Data Stewardship Committee. 2017. https://www.popdata.bc.ca/data. Accessed October 21, 2022.
   Google Scholar
• Williams J, Young W. Inventory of Studies on the Accuracy of Canadian Health Administrative Databases. Ontario: Institute for Clinical Evaluative Science;1996.
   Google Scholar
• Sariyar M, Borg A. The Recordlinkage Package: Detecting Errors in Data, Dec. 2010. The R Journal. 2010;212:61-7.
   Google Scholar
• R core team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2011. Available from: https://www.r-project.org/.
   Google Scholar
• Stephenson A, Hux J, Tullis E, Austin PC, Corey M, Ray J. Socioeconomic status and risk of hospitalization among individuals with cystic fibrosis in Ontario, Canada. Pediatr Pulmonol. 2011;46(4):376–384. doi:10.1002/ppul.21368.
   Google Scholar
• Drobnik A, Pinchoff J, Bushnell G, Terranova E, Fuld J. Matching New York City viral hepatitis, tuberculosis, sexually transmitted diseases and HIV surveillance data, 2000-2010. New York: New York City Department of Health and Mental Hygiene: Epi Research Report. 2013 Oct.
   Google Scholar
• Lee D, Lim S, Kaba F. Guide to probabilistic matching: Linking New York City correctional health and vital statistics data. New York, NY: New York City Department of Health and Mental Hygiene; 2016.
   Google Scholar
• Bank of Canada. Consumer price index, 2000 to present. 2017.
   Google Scholar
• Liang K, Zeger S. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73(1). doi:10.1093/biomet/73.1.13.
   Google Scholar
• Efron B, Tibshirani R. An Introduction to the Bootstrap. London: Chapman and Hall; 1993.
   Google Scholar
• Shah P, Lowery E, Chaparro C, Visner G, Hempstead SE, Abraham J, Bhakta Z, Carroll M, Christon L, Danziger-Isakov L, Diamond JM. Cystic fibrosis foundation consensus statements for the care of cystic fibrosis lung transplant recipients. The Journal of Heart and Lung Transplantation. 2021;40(7):539-56.
   Google Scholar
• Keller CA, Gonwa TA, White LJ, Rucci ME, Visscher SL, Kennedy CC, Daly RC, Naessens JM. Utilization and cost analysis of lung transplantation and survival after 10 years of adopting the Lung Allocation Score (LAS). Transplantation. 2019;103(3):638.
   Google Scholar
• Canadian Cystic Fibrosis Registry (CCFR). The Canadian Cystic Fibrosis Registry 2017 annual report. Toronto, ON, Canada; 2019.
   Google Scholar
• BC Ministry of Health. Expansion of drug eligibility for people with cystic fibrosis. 2022.
   Google Scholar
• Canadian Institutes of Health Information. National Health Expenditure Trends, 2021: Data Tables—Series D1 [Internet]. Ottawa, ON, Canada; 2021. Available from: https://www.cihi.ca/en/national-health-expenditure-trends. Accessed October 21, 2022.
   Google Scholar
• Grosse SD, Quynh T, Michelle MPH, Pharmd V, Feng LB, Jay D. Healthcare expenditures for privately insured US patients with cystic fibrosis, 2010-2016. Pediatr Pulmonol. 2018;53(12):1611–1618. doi:10.1002/ppul.24178.
   Google Scholar
• Johnson J a, Connolly M, Zuberbuhler P, Brown NE. Health-related quality of life for adults with cystic fibrosis: a regression approach to assessing the impact of recombinant human DNase. Pharmacotherapy. 2000;20(10):1167–1174. doi:10.1592/phco.20.15.1167.34583.
   Google Scholar
• Guerriere DN, Tullis E, Ungar WJ, et al. Economic Burden of ambulatory and home-based care for adults with cystic fibrosis. Treat Respir Med. 2006;5(5):351–359.
   Google Scholar
• Griese M, Costa S, Linnemann RW, Mall MA, McKone EF, Polineni D, Quon BS, Ringshausen FC, Taylor-Cousar JL, Withers NJ, Moskowitz SM. Safety and efficacy of elexacaftor/tezacaftor/ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del alleles: interim results of an open-label phase 3 clinical trial. American Journal of Respiratory and Critical Care Medicine. 2021;203(3):381-5.
   Google Scholar
• Skolnik K, Ronksley P, Pendharkar SR, Wick JP, Quon BS, Williamson T. Hospital costs of Canadian cystic fibrosis patients. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. 2022;6(3):145-52.
   Google Scholar
• Song JT, Desai S, Franciosi AN, Dagenais RV, Quon BS. The impact of elexacaftor/tezacaftor/ivacaftor on adherence to nebulized maintenance therapies in people with cystic fibrosis. Journal of Cystic Fibrosis. 2022;21(6):1080-1.
   Google Scholar
• Abdallah K, Boeck D, Dooms K, Simoens M. S. a comparative analysis of pricing and reimbursement of cystic fibrosis trans-membrane conductance regulator modulators in Europe. Front Pharmacol. 2021;12:746710.
   Google Scholar
• Canadian Cystic Fibrosis Registry (CCFR). Understanding the social and economic impact of life with cystic fibrosis; 2021.
   Google Scholar
• Frey S, Stargardt T, Schneider U, Schreyögg J. The economic burden of cystic fibrosis in Germany from a payer perspective. Pharmacoeconomics. 2019;37(8):1029–1039. doi:10.1007/s40273-019-00797-2.
   Google Scholar
• Canadian Institute for Health Information. National health expenditure trends, 1975 to 2019. Ottawa, ON: Canadian Institute for Health Information; 2019.
   Google Scholar